A pre-conference workshop examining AI’s future in pharmacometrics and four scientific poster presentations will mark PumasAI’s participation at ACoP 2026
PumasAI, an AI-powered clinical pharmacology and pharmacometrics firm that is revolutionizing how pharmaceutical teams operate, has unveiled its scientific program for the American Conference on Pharmacometrics (ACoP 2026), scheduled for October 11-14, 2026, at the Gaylord National Resort & Convention Center in Maryland.
PumasAI will feature a full-day pre-conference workshop on AI’s future in pharmacometrics, four scientific poster presentations, and a team of experts stationed at Booth #5. On October 11, from 9 a.m. to 5 p.m. EST, Dr. Niklas Korsbo will lead AI in Pharmacometrics: A Strategic Vision for the Next Five Years. Tailored for pharmacometrics leaders, R&D decision makers, and quantitative scientists, the workshop will examine the strategic and technical foundations of machine learning in pharmacometrics. The session will concentrate on how AI and machine learning can support pharmacometric thinking, decision making, and future modeling strategies.
Also worth a look: Mitolyn, Built Around the Purple Peel Exploit, has been Launched, Designed to Enhance Mitochondrial Health & Manage Weight and Out Today: “My Favorite Things” by Award-winning Vocalist Nicole Henry.
“ACoP brings together many of the people defining what comes next for pharmacometrics and model-informed drug development,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “This year, we are especially excited to contribute to the conversation around how AI and Scientific Machine Learning can help scientists translate increasingly sophisticated models into better, faster, and more confident drug development decisions.”
PumasAI’s Four Poster Presentations at ACoP 2026
Scientists from PumasAI will additionally present research covering population pharmacokinetics, exposure-response analysis, and AI-driven modeling:
● Population Pharmacokinetic Analysis of Taletrectinib in Healthy Subjects and Patients with ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC)
● DeepNLME Autonomously Rivals Expert-Specified Pharmacokinetic Functions for Mosunetuzumab
● Population Pharmacokinetic Analysis of An Oral Meloxicam Formulation (MR-107A-02) in Healthy Volunteers and Surgical Patients
● Meloxicam (MR-107A-02) Exposure-Response of Pain Relief in Post-Surgery Patients
“The research we are bringing to ACoP spans the work pharmacometricians are doing today and emerging approaches that could change how that work is done tomorrow,” added Dr. Ivaturi. “That is an exciting place for PumasAI to be.”
Throughout ACoP 2026, attendees are invited to Booth #5 for discussions on pharmacometrics, MIDD, AI, and Scientific Machine Learning. Further details about PumasAI’s presence at ACoP 2026 and registration for the pre-conference workshop can be found at https://pumas.ai/events/acop-2026-from-models-to-medicines-faster.
About PumasAI
PumasAI, an award-winning global healthcare intelligence firm, aims to accelerate precision healthcare to patients. Its proprietary software and AI tools comprise the Pumas product suite—an integrated modeling and simulation platform built to boost productivity throughout the drug development lifecycle. PumasAI scientists offer consulting services to top pharmaceutical innovators in areas including clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more.
To learn more, visit www.pumas.ai
Don F. McLean
McLean Media
+1 734-716-4182
email us here
